UA66758C2 - Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment - Google Patents
Pharmaceutical formulations comprising growth hormone, method for its production and method for treatmentInfo
- Publication number
- UA66758C2 UA66758C2 UA98105593A UA98105593A UA66758C2 UA 66758 C2 UA66758 C2 UA 66758C2 UA 98105593 A UA98105593 A UA 98105593A UA 98105593 A UA98105593 A UA 98105593A UA 66758 C2 UA66758 C2 UA 66758C2
- Authority
- UA
- Ukraine
- Prior art keywords
- growth hormone
- pharmaceutical formulations
- treatment
- production
- amino acid
- Prior art date
Links
- 102000018997 Growth Hormone Human genes 0.000 title abstract 3
- 108010051696 Growth Hormone Proteins 0.000 title abstract 3
- 239000000122 growth hormone Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000002265 Human Growth Hormone Human genes 0.000 abstract 1
- 108010000521 Human Growth Hormone Proteins 0.000 abstract 1
- 239000000854 Human Growth Hormone Substances 0.000 abstract 1
- -1 Leu or His Chemical class 0.000 abstract 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 239000013011 aqueous formulation Substances 0.000 abstract 1
- 230000006240 deamidation Effects 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 150000002411 histidines Chemical class 0.000 abstract 1
- 229960000502 poloxamer Drugs 0.000 abstract 1
- 229920001983 poloxamer Polymers 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK49096 | 1996-04-24 | ||
PCT/DK1997/000184 WO1997039768A1 (en) | 1996-04-24 | 1997-04-24 | A pharmaceutical formulation containing growth hormone, an amino acid and a non-ionic detergent |
Publications (1)
Publication Number | Publication Date |
---|---|
UA66758C2 true UA66758C2 (en) | 2004-06-15 |
Family
ID=8094154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UA98105593A UA66758C2 (en) | 1996-04-24 | 1997-04-24 | Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment |
Country Status (20)
Country | Link |
---|---|
US (1) | US20020077461A1 (pt) |
EP (2) | EP1629832A1 (pt) |
JP (2) | JP4176834B2 (pt) |
KR (1) | KR20000010630A (pt) |
CN (1) | CN1130223C (pt) |
AT (1) | ATE309819T1 (pt) |
AU (1) | AU733592B2 (pt) |
BR (1) | BR9708858A (pt) |
CA (1) | CA2252535C (pt) |
CZ (1) | CZ298292B6 (pt) |
DE (1) | DE69734653T2 (pt) |
DK (1) | DK0904099T3 (pt) |
ES (1) | ES2253774T3 (pt) |
HU (1) | HU229868B1 (pt) |
IL (2) | IL126463A0 (pt) |
NO (1) | NO323360B1 (pt) |
PL (1) | PL188222B1 (pt) |
RU (1) | RU2236250C2 (pt) |
UA (1) | UA66758C2 (pt) |
WO (1) | WO1997039768A1 (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981485A (en) * | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
KR100491282B1 (ko) | 1996-07-24 | 2005-05-24 | 워너-램버트 캄파니 엘엘씨 | 통증 치료용 이소부틸가바 및 그의 유도체 |
CA2309818C (en) * | 1997-11-12 | 2009-05-05 | Alza Corporation | Buffered drug formulations for transdermal electrotransport delivery |
GB9803448D0 (en) * | 1998-02-18 | 1998-04-15 | Pharma Mar Sa | Pharmaceutical formulation |
JP4711520B2 (ja) * | 2000-03-21 | 2011-06-29 | 日本ケミカルリサーチ株式会社 | 生理活性ペプチド含有粉末 |
KR20030038690A (ko) | 2000-08-07 | 2003-05-16 | 인헤일 테라퓨틱 시스템즈 인크. | 응집이 최소화된, 흡입성 분무 건조 4-나선 다발 단백질분말 |
CA2516314C (en) * | 2003-03-18 | 2012-01-03 | Ares Trading Sa | Liquid growth hormone formulation and process of preparation thereof |
KR101198550B1 (ko) * | 2003-03-24 | 2012-11-06 | 플루로메드, 인코포레이티드 | 역성 열감응 중합체를 사용하는 일시적인 색전화 |
DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
US7700086B2 (en) * | 2003-11-06 | 2010-04-20 | Pluromed, Inc. | Internal clamp for surgical procedures |
WO2005063298A1 (en) * | 2003-12-23 | 2005-07-14 | Pharmacia Corporation | Stable growth hormone liquid formulation |
AU2005237775B2 (en) * | 2004-04-07 | 2010-03-04 | Ares Trading S.A. | Liquid growth hormone formulation |
CN101356269A (zh) * | 2004-12-22 | 2009-01-28 | Ambrx公司 | 表达和纯化重组人类生长激素的方法 |
MX2007007580A (es) * | 2004-12-22 | 2007-12-11 | Ambrx Inc | Hormona del crecimiento humana modificada. |
US7816320B2 (en) * | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
BRPI0615351A2 (pt) | 2005-08-30 | 2011-05-17 | Novo Nordisk Healthcare Ag | formulações lìquidas de hormÈnio do crescimento peguilado |
WO2007033427A1 (en) * | 2005-09-23 | 2007-03-29 | Metabolic Pharmaceuticals Limited | Stabilisation of peptides with basic amino acids |
CN1939534B (zh) * | 2005-09-27 | 2010-12-01 | 长春金赛药业股份有限公司 | 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂 |
LT2049148T (lt) | 2006-07-06 | 2016-11-25 | Daewoong Co., Ltd. | Žmogaus augimo hormono skysta stabili kompozicija |
RU2009103198A (ru) | 2006-07-07 | 2010-08-20 | Ново Нордиск Хелс Кеа Аг (Ch) | Новые белковые конъюгаты и способы их получения |
WO2008076819A2 (en) * | 2006-12-18 | 2008-06-26 | Altus Pharmaceuticals Inc. | Human growth hormone formulations |
TWI508737B (zh) | 2010-01-22 | 2015-11-21 | 諾佛 儂迪克股份有限公司 | 具有延長的活體內功效的生長激素 |
JP5980689B2 (ja) | 2010-01-22 | 2016-08-31 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | 安定な成長ホルモン化合物 |
KR101337797B1 (ko) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
US8765411B2 (en) * | 2010-09-21 | 2014-07-01 | Ferring B.V. | Process for production of recombinant human growth hormone from E. coli cells |
US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
WO2014004376A2 (en) | 2012-06-26 | 2014-01-03 | Del Mar Pharmaceuticals | Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof |
US11045523B2 (en) | 2013-04-05 | 2021-06-29 | Novo Nordisk Healthcare Ag | Formulation of growth hormone albumin-binder conjugate |
US11491154B2 (en) | 2013-04-08 | 2022-11-08 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
AU2014293011A1 (en) | 2013-07-26 | 2016-03-17 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene |
RU2683823C2 (ru) * | 2013-09-27 | 2019-04-02 | Ханми Фарм. Ко., Лтд. | Препарат гормона роста человека длительного типа |
US9119832B2 (en) | 2014-02-05 | 2015-09-01 | The Regents Of The University Of California | Methods of treating mild brain injury |
WO2017075535A1 (en) | 2015-10-28 | 2017-05-04 | Oxeia Biopharmaceuticals, Inc. | Methods of treating neurodegenerative conditions |
KR102655498B1 (ko) | 2017-09-07 | 2024-04-11 | 제이씨알 파마 가부시키가이샤 | 수성 의약 조성물 |
CN117771250A (zh) | 2018-06-29 | 2024-03-29 | 因赛特公司 | Axl/mer抑制剂的制剂 |
CN115634284A (zh) * | 2022-10-31 | 2023-01-24 | 景泽生物医药(合肥)有限公司 | 一种促性腺激素冻干制剂及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
DK204791D0 (da) * | 1991-12-20 | 1991-12-20 | Novo Nordisk As | Hidtil ukendt farmaceutisk praeparat |
AU667503B2 (en) * | 1991-12-20 | 1996-03-28 | Novo Nordisk Health Care Ag | A stabilized pharmaceutical formulation comprising growth hormone and histidine |
ES2153385T5 (es) * | 1992-07-31 | 2008-09-01 | Genentech, Inc. | Composicion acuosa a base de hormona del crecimiento humana. |
-
1997
- 1997-04-23 US US08/842,293 patent/US20020077461A1/en not_active Abandoned
- 1997-04-24 AT AT97918073T patent/ATE309819T1/de active
- 1997-04-24 AU AU26343/97A patent/AU733592B2/en not_active Expired
- 1997-04-24 KR KR1019980708535A patent/KR20000010630A/ko active Search and Examination
- 1997-04-24 CA CA002252535A patent/CA2252535C/en not_active Expired - Lifetime
- 1997-04-24 CN CN97194040A patent/CN1130223C/zh not_active Expired - Lifetime
- 1997-04-24 WO PCT/DK1997/000184 patent/WO1997039768A1/en active IP Right Grant
- 1997-04-24 DE DE69734653T patent/DE69734653T2/de not_active Expired - Lifetime
- 1997-04-24 EP EP05110701A patent/EP1629832A1/en not_active Withdrawn
- 1997-04-24 BR BR9708858A patent/BR9708858A/pt not_active Application Discontinuation
- 1997-04-24 CZ CZ0320798A patent/CZ298292B6/cs not_active IP Right Cessation
- 1997-04-24 EP EP97918073A patent/EP0904099B1/en not_active Expired - Lifetime
- 1997-04-24 PL PL97329386A patent/PL188222B1/pl unknown
- 1997-04-24 DK DK97918073T patent/DK0904099T3/da active
- 1997-04-24 RU RU98121135/15A patent/RU2236250C2/ru active
- 1997-04-24 UA UA98105593A patent/UA66758C2/xx unknown
- 1997-04-24 JP JP53762297A patent/JP4176834B2/ja not_active Expired - Lifetime
- 1997-04-24 ES ES97918073T patent/ES2253774T3/es not_active Expired - Lifetime
- 1997-04-24 IL IL12646397A patent/IL126463A0/xx active IP Right Grant
- 1997-04-24 HU HU9902476A patent/HU229868B1/hu unknown
-
1998
- 1998-10-04 IL IL126463A patent/IL126463A/en not_active IP Right Cessation
- 1998-10-23 NO NO19984951A patent/NO323360B1/no not_active IP Right Cessation
-
2008
- 2008-06-03 JP JP2008145780A patent/JP2008231124A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP0904099A1 (en) | 1999-03-31 |
NO984951D0 (no) | 1998-10-23 |
ES2253774T3 (es) | 2006-06-01 |
CZ320798A3 (cs) | 1999-03-17 |
PL188222B1 (pl) | 2004-12-31 |
PL329386A1 (en) | 1999-03-29 |
CA2252535A1 (en) | 1997-10-30 |
CA2252535C (en) | 2009-06-23 |
HUP9902476A2 (hu) | 2000-11-28 |
IL126463A (en) | 2007-06-17 |
JP4176834B2 (ja) | 2008-11-05 |
CZ298292B6 (cs) | 2007-08-15 |
US20020077461A1 (en) | 2002-06-20 |
CN1216472A (zh) | 1999-05-12 |
HUP9902476A3 (en) | 2000-12-28 |
DE69734653T2 (de) | 2006-08-10 |
JP2008231124A (ja) | 2008-10-02 |
RU2236250C2 (ru) | 2004-09-20 |
IL126463A0 (en) | 1999-08-17 |
DK0904099T3 (da) | 2006-03-06 |
CN1130223C (zh) | 2003-12-10 |
ATE309819T1 (de) | 2005-12-15 |
AU2634397A (en) | 1997-11-12 |
NO984951L (no) | 1998-10-23 |
AU733592B2 (en) | 2001-05-17 |
KR20000010630A (ko) | 2000-02-25 |
NO323360B1 (no) | 2007-04-10 |
EP1629832A1 (en) | 2006-03-01 |
JP2000508665A (ja) | 2000-07-11 |
BR9708858A (pt) | 1999-08-03 |
EP0904099B1 (en) | 2005-11-16 |
DE69734653D1 (de) | 2005-12-22 |
HU229868B1 (en) | 2014-10-28 |
WO1997039768A1 (en) | 1997-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA66758C2 (en) | Pharmaceutical formulations comprising growth hormone, method for its production and method for treatment | |
MD1699F2 (ro) | Compoziţie apoasă a hormonului somatotrop uman şi procedeu de prevenire a denaturării ei | |
IL152659A (en) | Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer | |
WO2002048183A3 (en) | Compositions of peptide crystals | |
EP1025840A3 (en) | Oral drug compositions and methods | |
EP1810715A3 (en) | Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity | |
HUP0004560A2 (hu) | Törést gyógyító PTHrP analógok | |
EP1033998A4 (en) | METHOD FOR SUPPRESSING BETA AMYLOID-RELATED CHANGES IN ALZHEIMER | |
WO2002043750A3 (en) | Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations | |
WO1994008551A3 (en) | Pharmaceutical compositions and methods for treating cold symptoms | |
DE60000288D1 (de) | Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten | |
WO2003028623A3 (en) | Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucuous membranes | |
EE9900428A (et) | Köhavastased ravimkoostised | |
WO2003047500A3 (en) | Vaccine and method for treatment of motor neurone diseases | |
CA2303395A1 (en) | Treatment of obesity | |
SE9801495D0 (sv) | Protein formulationa | |
HUP0003840A2 (hu) | Szabályozott hatóanyagleadású gyógyászati készítmények | |
WO2002051379A3 (en) | Thixotropic nasal spray | |
GB2328872B (en) | Method for preparing pharmaceutical formulations | |
IL145722A0 (en) | Pharmaceutical composition comprising growth hormone and interferon | |
CA2429793A1 (en) | Interferon therapeutic effect enhancer | |
BG103905A (en) | New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine | |
NZ333656A (en) | Liquid formulation comprising less 5% w/w saturated polyglycosylated C8-10 glycerides (capryl caproyl macrogol glycerides) and a non-peptide for oro-mucosal administration | |
CA2237643A1 (en) | Therapeutic agent for acute hepatic failure | |
PT1448220E (pt) | Agente farmacêutico contendo uma substância activa antiflogística e hidrolisado de lactalbumina e respectiva utilização |